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Abstract
Introduction: Common medications used to treat mild persistent asthma are
glucocorticoids, leukotriene receptor antagonists and theophylline. The aim of
the study was to evaluate monotherapy with either inhaled steroids, oral
leukotriene receptor antagonist or theophylline in Egyptian children with mild
persistent asthma by determining their clinical, laboratory and spirometric
responses to treatment.
Material and methods: Thirty-nine mild asthmatic children between 8 and 13
years of age were included in the study. Patients were classified according to
therapy received into four groups: oral leukotriene receptor antagonist
(montelukast), inhaled corticosteroid (fluticasone propionate), sustained-release
(SR) theophylline, and no treatment. Pulmonary function testing was performed
at the start of therapy and 8 weeks later using spirometry. Eosinophil count and
serum nitric oxide were estimated in the blood. Minitab statistical package was
used for analysis of data.
Results: Follow-up after 8 weeks revealed significant improvement in FEV1% in
groups 1 (p < 0.01) and 3 (p < 0.05), significant improvement in PEFR in groups 1
(p < 0.05) and 2 (p < 0.01), significant decline in serum NO levels in groups 1 
(p < 0.05) and 2 (p < 0.05), as well as significant improvement in eosinophil
count in groups 1, 2 and 3 (p < 0.01, < 0.001, < 0.01 respectively). There was
a statistically significant positive correlation between the decline in serum NO
and the decline in blood eosinophil % in group 2 (p < 0.05).
Conclusions: Inhaled corticosteroids and montelukast have a significant role in
controlling the pulmonary functions and the inflammatory process in children
with mild persistent asthma, although inhaled corticosteroids seem to yield
a better response. Children with mild persistent asthma should receive
a controller medication, and SR theophylline may be a good cost-benefit
alternative for low socio-economic groups of patients.
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Introduction 
Asthma is a chronic inflammatory condition of the lung airways resulting
in episodic airflow obstruction. This chronic inflammation heightens the
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airways’ hyper-responsiveness (AHR) to provocative
exposures [1].
Asthma is a relatively common chronic disease,
affecting 3% to 38% of children worldwide [2].
Moreover, it is the highest ranking chronic condition
causing hospitalization as well as being the primary
chronic illness resulting in school absences [3].
Throughout the world, asthma morbidity and
mortality appear to be increasing [4, 5].
According to GINA guidelines for asthma therapy,
the daily controller medication for mild persistent
asthma is low dose inhaled glucocorticoid [6]. Other
treatment options include sustained-release
theophylline, chromone, and leukotriene modifiers.
Corticosteroids are the most potent and
consistently effective long-term-control medication
for asthma. Their broad action on the inflammatory
process may account for their efficacy as preventive
therapy. Their clinical effects include reduction in
severity of symptoms, improvement in peak
expiratory flow and spirometry, diminished airway
hyper-responsiveness, prevention of exacerbations,
and possibly the prevention of airway wall
remodelling [7].
Leukotrienes are released by several types of
cells and can cause bronchoconstriction and
inflammation [8]. Leukotriene modifiers comprise
two pharmacological classes of compounds: 
5-lipoxygenase pathway inhibitors (e.g., zileuton),
and leukotriene receptor antagonists (LTRAs), e.g.,
zafirlukast and montelukast [9]. Montelukast can
be used for children as young as 6 months of age
[10], whereas zafirlukast can be used only for
children older than 7 years [11].
Leukotriene receptor antagonists (LTRAs) inhibit
the effects of cysteinyl leukotrienes, which are
chemical mediators of asthma. LTRAs competitively
block leukotriene receptors on bronchial smooth
muscle and elsewhere [12]. Thus, they exert anti-
inflammatory properties and can reduce or prevent
airway eosinophilia [13], in addition to their ability to
attenuate AHR [14]. They can improve asthma
symptoms and airway function, and reduce asthma
exacerbations [15]. As a result, leukotriene
antagonists have been acknowledged by some
guidelines as acceptable first line long-term controller
therapies for mild persistent asthma [7, 16].
Previous studies have shown that theophylline
could be effective as monotherapy and as add-on
treatment to inhaled or oral glucocorticosteroids in
children older than 5 years. It is significantly more
effective than placebo at controlling day and night
symptoms and improving lung function.
Maintenance treatment offers a marginal protective
effect against exercise-induced bronchoconstriction.
Sustained-release products are preferable for
maintenance therapy, since they enable twice-daily
dosing [17].
Monitoring of airway inflammation in bronchial
asthma could be done by measurement of nitric
oxide (NO), which is assessed directly by sputum
examination, and indirectly by its measurement in
peripheral blood [18].
Nitric oxide, a small molecule and a strong free
radical, influences many aspects of pulmonary
functions in healthy subjects and patients. It is
synthesized from the amino acid L-arginine by nitric
oxide synthase (NOS), which exists in three forms.
After production, NO can be exhaled, metabolized
to nitrite and nitrate, or interacts with superoxide
to form peroxynitrite. Determination of NO itself is
difficult because of its radical nature and very short
half-life. Therefore, determination of the stable end
products of the NO radical in the plasma such as
nitrite and nitrate is the most frequently used
method to measure the production of the NO
radical [19].
The aim of the present study is to evaluate
monotherapy with different drugs (inhaled steroids,
oral leukotriene receptor antagonist or SR
theophylline) in Egyptian children with mild
persistent asthma by determining the clinical and
laboratory responses as well as their effect on
spirometric parameters.
Material and methods  
Study design
A randomized parallel group study was
conducted to compare the effect of anti-asthmatic
monotherapy (inhaled corticosteroids [ICS],
leukotriene receptor antagonists [LTRAs] and SR
theophylline) on mild asthmatic Egyptian children.
The study included 39 asthmatic children (20
females and 19 males) between the ages of 8 and
13 years. They all completed an 8-week study
period. All patients were diagnosed as having mild
persistent asthma based on the classification of
asthma severity according to GINA Guidelines
(2009) [17] and were attending the Allergy Clinic of
Children’s Hospital, Cairo University for routine
visits. The selection was based on the following
inclusion and exclusion criteria:
Inclusion criteria: The study group included
children aged 8-13 years who were able to perform
pulmonary function tests efficiently; had a history
of mild persistent asthma; were healthy, non-
smokers (active smoking); were not in acute
exacerbation; did not receive any anti-asthmatic
therapy before the study (1 month for steroids, 
2 weeks for theophylline and 1 week for long acting
β 2 agonist).  
Exclusion criteria: children who had any
respiratory disorder other than asthma; children
who had symptoms and signs of upper respiratory
tract infection within 3 weeks of the study.Arch Med Sci 6, December / 2010 921
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The patients were randomly distributed into four
groups:
• Group 1: 11 patients (4 females and 7 males) were
receiving a selective and orally active leukotriene
receptor antagonist (montelukast sodium 5 mg
per day chewable tablets once daily, at bedtime)
• Group 2: 11 patients (6 females and 5 males) were
receiving inhaled corticosteroids (fluticasone
propionate, at a dose of 100 μg twice daily,
supplied as an Evohaler, a pressurized inhalation
suspension, delivering 50 μg per action as oral
inhalation) for 8 weeks.
• Group 3: 10 patients (7 females and 3 males) were
receiving sustained-release theophylline (theo  -
phy  lline anhydrous, oral tablets in a dose of
15 mg/kg/day divided into two doses every 12
hours) for 8 weeks.
• Group 4: 7 patients (3 females and 4 males) were
receiving no regular medication for 8 weeks, and
were considered as a control group.
Asthma was stable and considered clinically well
controlled in all patients; treatment remained
unchanged throughout the whole study period.
The following steps were performed for each
child at the beginning of the study, and 8 weeks
later.
1.  Thorough medical history was taken with
emphasis upon symptoms of asthma,
precipitating factors, family history, and impact
of asthma on patient and family. 
2. Clinical examination included recording of vital
signs, anthropometric measurements, and
detailed physical examination
3. Pulmonary function testing was performed at the
beginning of the study and 8 weeks later using
a spirometer (Fukuda Denshi, Spirosift SP5000).
At least three technically accepted manoeuvres
were performed and the highest value was
recorded.
4.  Measurement of eosinophil count %: blood
samples were collected at the first visit and 
8 weeks later. Blood films were prepared from
EDTA anticoagulated blood and then stained with
Leishman stain. The blood films were examined
and recorded as a percentage where eosinophils
were counted in 100 white blood cells.
5. Measurement of serum nitric oxide: nitric oxide
was assessed in the serum of patients at the
onset of the study and 8 weeks later using Total
NO/Nitrite/Nitrate Assay Kit, for the quantitative
determination of nitric oxide concentration in
serum, supplied by R&D systems Europe, Ltd.
Abingdon, OX14 3NB United Kingdom. 
Sample Preparation: blood samples were
collected in plain tubes and then centrifuged for 
15 min at 100 revolutions per min (rpm) to obtain
serum. Serum aliquots were collected and stored
at ≤ 20°C until assay was performed. Repeated
freeze-thaw cycles were avoided. Prior to assay,
serum samples were filtered through a 10 or 30 kDa
molecular weight cut-off filter.
Written consent to participate in the study was
obtained from every child’s care-taker according to
guidelines approved by the ethical committee of
the National Research Centre.
Statistical analysis
Minitab statistical package was used for analysis
of data. All data were expressed as mean and
standard deviation of the mean (mean ± SD).
Different data were analysed by paired t-test. One-
way analysis of variance (ANOVA) was performed
to test the equality of the means of different
treatments. Tukey’s method was used to compare
all pairwise differences between level means. The
relationship between studied parameters was
assessed using Pearson’s linear correlation
coefficient (r). A p value < 0.05 was considered
significant.
Results 
Table I shows the values of the different studied
parameters in the four groups before and 8 weeks
after treatment. Values show improvement in
pulmonary functions and nitric oxide in patients
receiving treatment by the different modalities.
Figures 1-4 show the changes that occurred in each
parameter, namely, FEV1%, PEFR%, NO and Eosin%,
respectively, before and 8 weeks after treatment
with a different modality. The improvement in
FEV1% after treatment was statistically significant
in groups 1 and 3 (p < 0.01, p < 0.05 respectively),
whereas FEV1% became worse in group 4 (Figure 1).
As regards the peak expiratory flow rate (PEFR), it
showed improvement in the three groups, which
reached statistical significance in groups 1 and 2 
(p < 0.05, p < 0.01 respectively), whereas PEFR
became worse in group 4 (Figure 2). The evaluation
of mean serum levels of nitric oxide (NO) revealed
a significant decrease in groups 1 and 2 after
treatment (p < 0.05), while there was a non-
significant decrease in group 3 (Figure 3). Patients
in group 4 who received no treatment showed an
increase in mean NO levels and worsening of their
condition. As for the percentage of blood
eosinophils (Eosin%), our results showed significant
improvement after treatment in the first three
groups (p < 0.01) (Figure 4). Table II shows the
different correlations between the changes in NO
versus the changes in FEV1, PEFR and Eosin% in the
four studied groups, where there was a statistically
significant (p = 0.014) positive correlation (r = 0.714)
between the decline in the serum nitric oxide and
the decline in the blood eosinophil % in group 2,
which received inhaled fluticasone for 8 weeks. 922 Arch Med Sci 6, December / 2010
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Group 1 (n = 11) Group 2 (n = 11) Group 3 (n = 10) Group 4 (n = 7)
(Montelukast)F luticasone)( S R-Theophylline)( N o medication)
Baseline Day 56 Baseline Day 56 Baseline Day 56 Baseline Day 56
x
– ± SD x
– ± SD x
– ± SD x
– ± SD x
– ± SD x
– ± SD x
– ± SD x
– ± SD
Age 10.0 ±1.95 9.7 ±2.01 9.6 ±0.97 9.9 ±2.91
FEV1 % 68 ±10* 78 ±13* 72 ±15 81 ±11 76 ±9* 86 ±11* 75 ±14 73 ±21
PEFR% 63 ±17* 76 ±11* 59 ±15* 75 ±15* 65 ±18 73 ±11 67 ±19 62 ±17
NO [μmol/l] 4.9 ±3.9* 2.2 ±2.1* 3.2 ±2.5* 1.4 ±1.7* 3.7 ±2.4 2.3 ±2.7 2.4 ±3.6 4.5 ±5.2
Eosin% 6.0 ±2.0* 3.0 ±1.0* 9.0 ±4.0* 4.0 ±3.0* 5.0 ±3.0* 2.0 ±2.0* 3.0 ±2.0 2.0 ±1.0
Table I. Comparative data of FEV %, PEFR%, serum nitric oxide (NO) and Eosin% at baseline and 8 weeks after
treatment
* p = significant (p < 0.05) improvement in parameter after 8 weeks of treatment; for FEV % p = 0.007 and 0.012 (in groups 1 and 3 respectively); 
for PEFR% p = 0.028 and 0.003 (in groups 1 and 2 respectively); for NO p = 0.041 and 0.026 (in groups 1 and 2 respectively); and for Eosin% 
p = 0.001, 0.000 and 0.002 (in groups 1, 2 and 3 respectively) 
FEV1% – forced expiratory flow rate at first second as percentage of that predicted, PEFR% – peak expiratory flow rate as percentage of that
predicted, Eosin% – eosinophil count as percentage of eosinophils 
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Figure 1. Changes in forced expiratory volume in 1st
second (FEV1) before and after treatment in the
different studied groups
LTA– leukotriene antagonist, ICS – inhaled corticosteroid, 
Sr-Th – theophylline, cont. – control
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Figure 2. Changes in peak expiratory flow rate (PEFR)
before and after treatment in the different studied
groups
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Figure 3. Changes in serum nitric oxide (NO) level
before and after treatment in the different studied
groups
N
O
 
[
M
m
o
l
/
l
]
10
8
6
4
2
0
LTA                   ICS                 SrTh                Cont.
Treatment
P = 0.001
P = 0.000
P = 0.002
P = 0.103
Figure 4. Changes in blood eosinophils (%) before
and after treatment in the different studied groups
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Discussion
In the present work, different modes of
monotherapy for mild persistent asthma were
evaluated: namely a leukotriene receptor antagonist
(montelukast), inhaled corticosteroid (ICS)
(fluticasone), and SR theophylline. The control group
consisted of a group of patients who did not receive
any preventive medication during the study period. 
The results of pulmonary function tests in the
studied groups (Table I) showed that there was
improvement in FEV1% after 8 weeks of treatment,
which was statistically significant in groups 1 and
3 (Figure 1). As regards the peak expiratory flow rate
(PEFR), improvement was statistically significant in
groups 1 and 2 (Figure 2). 
Published data comparing the effects of ICS
versus montelukast on pulmonary functions are
inconsistent. Concerning the improvement in
FEV1%, our results are consistent with those of
Mandeep et al. [20], who demonstrated marked
improvement in FEV1 in those receiving
montelukast compared to placebo, yet it was not
superior to ICS. 
As regards % PEFR change, similar results were
obtained in different studies [21, 22], which revealed
improvement in % PEFR in two groups of patients
receiving oral montelukast and fluticasone inhaler
for a period of 12 weeks with no significant
difference between the groups. In a prospective 
12-month observational analysis [23], and in
a randomized double-blind 6-week study [24],
similar results were obtained.
In contrast, a multicentre, randomized, double-
blind study by Busse and Lemanske [25] concluded
that treatment with fluticasone resulted in
significantly greater improvement in FEV1, FVC and
PEFR compared with montelukast. These results
agree with other previous studies [26-28].
The evaluation of mean serum levels of nitric
oxide (NO) in the present work revealed
a significant decrease in groups 1 and 2 eight weeks
after treatment (Figure 3). Patients in group 4 who
received no treatment showed an increase in mean
NO levels and worsening of their condition.
Although measurement of NO can be performed
directly by its estimation in exhaled air, due to
technical problems encountered in this study, NO
was measured in serum by an indirect method.
Nitric oxide is synthesized mainly through NO
synthase enzymes. In particular, NO derived from
the inducible isoform of NOS (iNOS) seems to be
implicated in inflammatory diseases such as
asthma, where it is supposed to be a pro-
inflammatory mediator with immunomodulatory
effects [29]. Several studies have shown that the
secreted pro-inflammatory cytokines lead to an
increase of NO levels in exhaled air, plasma and
serum of patients with asthma compared with
healthy individuals [30-32].
The present results showed a non-significant 
(p = 0.06) decline in the mean NO levels in group 1
(montelukast) and group 2 (fluticasone); however,
the lower mean level of NO attained with ICS could
affirm their role as better controller medications.
Ricciardolo et al. [29] postulated that asthma
treatment with corticosteroids resulted in
a reduction of expired NO levels due to both the
reducing effects of steroids on the underlying
airway inflammation in asthma and the inhibitory
effects on iNOS expression itself. Since our main
concern was to assess the effect of the studied
drugs on the levels of NO, we referred to other
publications confirming the decline in NO levels in
exhaled air following treatment with inhaled
steroids [33, 34]. 
As for the percentage of blood eosinophils
(Eosin%), our results showed significant
improvement in all studied patients receiving
medications (Figure 4). Eosin% showed a sta  -
tistically significant difference among the 4 groups
at the end of the study period, where fluticasone
was superior to montelukast and theophylline. This
might be due to the mode of action of
corticosteroids causing a reduction in eosinophil
count in addition to their role as anti-inflammatory
agents.
Our results were confirmed by another
comparative study which demonstrated a reduction
in blood eosinophils with both montelukast and
fluticasone but with greater significant reduction
with fluticasone, after 12-month therapy in children
with mild persistent asthma [26].
On the other hand, a randomized, double-blind
6-week study [35] compared the effect of
montelukast and inhaled beclomethasone on blood
eosinophils, and concluded that eosinophils
decreased with both modalities, but with more
decline in favour of montelukast rather than inhaled
beclomethasone.
In a study conducted by Hassan et al. [21], the
mean absolute eosinophil count showed
a significant reduction in both the montelukast
group and in the inhaled steroid group, with no
statistically significant difference between the two
groups.
The results of the present study showed
a significant positive correlation (p = 0.014; 
r = 0.714) between the decline in serum nitric oxide
and the decline in blood eosinophils in group 2
patients who received inhaled fluticasone for 
8 weeks (Table II). 
In contrast, in a study by Jang and Choi [36],
comparing the role of nitric oxide metabolites in
induced sputum versus blood, they found no
correlation between serum nitric oxide and
eosinophils in asthmatic patients.924 Arch Med Sci 6, December / 2010
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In conclusion, this study shows that both 
ICS (fluticasone) and LTA (montelukast) have
a significant role in controlling the pulmonary
functions and the inflammatory process in children
with mild persistent asthma; however, ICS seems
to yield a better response for most of the studied
parameters. Eosinophil count follow-up has an
important role in the evaluation of therapy. Mild
persistent asthmatic children should receive
a controller medication, and SR theophylline may
be a good cost-benefit alternative for low socio-
economic groups of patients.
Further studies including a larger sample size are
required to validate the relationship between the
pulmonary functions and nitric oxide, and also to
assess the effect of the genetic background and
gender as well as environmental factors of our
country on the results achieved. 
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